| Nov 7 |
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma
|
| Nov 4 |
Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea
|
| Oct 31 |
Fortress Biotech Insiders Placed Bullish Bets Worth US$4.49m
|
| Oct 25 |
Highbridge Capital Management's Strategic Acquisition of Fortress Biotech Shares
|
| Oct 25 |
Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference
|
| Oct 24 |
Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds
|
| Oct 9 |
Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit
|
| Sep 27 |
Fortress Biotech files to sell 6.19M shares of common stock for holders
|
| Sep 26 |
Fortress Biotech to Participate in October 2024 Investor Conferences
|
| Sep 20 |
Why Fortress Biotech (FBIO) Stock Is Getting Hammered
|
